Chemotherapy
VIDEO: Sitravatinib plus nivolumab does not offer OS benefit over docetaxel in NSCLC subset
Healio spoke with Hossein Borghaei, DO, MS, about results from the SAPPHIRE trial presented at this year’s ESMO Congress.
‘All hands on deck’ needed to navigate oncology drug shortages, says expert panel
A virtual town hall meeting featuring a panel of regulatory, pharmacy and procurement experts addressed the ongoing shortage of oncology drugs.
Malnutrition linked to poor outcomes after surgery for head and neck cancer
More than 20% of patients undergoing surgery for head and neck cancer are malnourished, according to data published in JAMA Otolaryngology Head & Neck Surgery.
FDA amends gastric cancer indication for Keytruda
The FDA revised an existing indication of pembrolizumab for the first-line treatment of certain patients with gastric or gastroesophageal junction adenocarcinoma.
FDA approves Fruzaqla for treatment of refractory metastatic colorectal cancer
The FDA approved fruquintinib for certain adults with previously treated metastatic colorectal cancer.
Race linked to quality, timeliness of care in adults with early-onset colorectal cancer
Black individuals with early-onset colorectal cancer received worse and less timely care compared with white patients, according to results of a national hospital-based study.
New approaches show promise for treatment of gastroesophageal cancers
Two different treatment regimens showed efficacy among patients with gastroesophageal cancers, according to study results presented during an ASCO Plenary Series session.
VIDEO: Amivantamab plus chemo ‘new standard of care’ in EGFR-mutated NSCLC after progression
MADRID — Amivantamab plus chemotherapy improved PFS, objective response rate and intracranial PFS compared with chemotherapy alone in patients with EGFR-mutated advanced non-small cell lung cancer after progression on osimertinib.
Taking a multidisciplinary approach to in-transit melanoma treatment
CHICAGO — A speaker at the American Society for Dermatologic Surgery Annual Meeting discussed how a multidisciplinary approach may be necessary for the treatment of in-transit melanoma.
ALK inhibitor improves DFS in ALK-positive NSCLC
MADRID — Alectinib significantly improved DFS compared with chemotherapy alone in patients with resected ALK-positive non-small cell lung cancer, according to research presented at ESMO Congress 2023.